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Moyamoya syndrome (MMS) is a chronic progressive cerebrovascular condition characterized
by bilateral stenosis/occlusion of the terminal internal carotid artery (ICA) often extending to
neighboring cerebral arteries with prominent collateral circulation and increased risk of hem-
orrhage. Symptoms include stroke, TIA, and headache.1 MMS’s etiology is unknown. However,
experimental evidence from arterial smooth muscle cells (SMC) derived from patients with
MMS has suggested that interleukin-1 beta (IL-1β)-dependent prostaglandin overproduction
plays a crucial role in its pathogenesis.2 Neonatal onset multisystem inflammatory disease
(NOMID) is an autosomal dominantly inherited disease characterized by excessive IL-1β-
overproduction and autoinflammation. Accordingly, NOMID is treated with IL-1 receptor
antagonists such as anakinra (Kineret, Swedish Orphan Biovitrum AB, Sweden, Stockholm) or
IL-1 receptor antibodies such as canakinumab (Ilaris, Novartis, Basel, Switzerland).3 We here
report the development of MMS in a NOMID patient. In this patient, escalation of IL-1
receptor antagonistic treatment led to a significant reduction of disease activity and TIAs. Both
the occurrence of MMS in this NOMID patient and the clinical and laboratory improvement
because of IL-1 receptor antagonism provide direct clinical evidence that IL-1β overproduction
could play a pathophysiologic role in MMS.
Case report
A novel NOMID-causing mutation (S331R mutation of the CIAS1 gene) was identified and
published when the patient was 4 years old.4 Genetic testing was performed because the patient
showed neonatal onset urticaria-like rash, fever, laboratory findings of systemic inflammation,
hepatosplenomegaly, facial features with frontal bossing and saddleback nose, arthritis, and
chronic inflammation of the CNS with sensorineural deafness. The mutation led to an over-
production of IL-1β, multisystem autoinflammation, and aseptic meningitis characterized by
blood-brain barrier impairment (BBBI). His symptoms showed an excellent response to IL-1
receptor antagonistic treatment with anakinra.4 NOMID disease activity remained well con-
trolled until the age of 16 when anakinra was discontinued and treatment with canakinumab
was started. Anakinra requires a daily subcutaneous application, whereas canakinumab is more
practical because it is only administered once in every 8 weeks. However, at age 19, the patient
presented to our stroke unit with a 2-year history of occipital headache and recurrent, in-
creasingly more intense and frequent TIAs associated with hypesthesia of the right upper limb.
Digital subtraction angiography showed occlusion of the left terminal ICA/anterior cerebral
artery (A1)/middle cerebral artery (M1) segment with MMS-typical prominent arterial col-
lateral circulation and stenosis of the right ICA/A1/M1 segment (figure e-1, links.lww.com/
NXI/A339). CSF analysis demonstrated pleocytosis (368/μL) and elevated protein (889.5
mg/L) indicating BBBI. CSF cytokines IL-1β, IL-6, and interferon-gamma induced protein 10
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kD (IP-10) were significantly increased (table). No infectious
agents were detected. Serum analysis revealed elevated in-
flammatorymarkers and cytokines including IL-1β, IL-6, and IP-
10 (table). We changed treatment from canakinumab to high-
dose anakinra 8mg/kg body weight/d based on a previous study
of CSF biomarkers that had suggested superiority of anakinra
over canakinumab especially in the intrathecal compartment.5
Follow-up CSF analysis showed a significant decrease of pleo-
cytosis (47/μL), normal protein levels (412 mg/L), and a sig-
nificant reduction of CSF cytokines after only 1 week.
Simultaneous serum analysis showed reduced inflammatory
parameters (table). At the follow-up 3 months later, the patient
showed a near-complete clinical recovery with no further TIAs
and significantly less headache. CSF analysis revealed even
milder pleocytosis (29/μL) and normal protein content (395
mg/L). Serum analysis demonstrated no signs of systemic in-
flammation anymore (table). MRI and magnetic resonance
angiography vessel wall imaging did not reveal changes.
Discussion
The etiology of MMS is largely unknown. However, BBBI is
characteristic for MMS and has been suggested to play a role in
MMS pathogenesis.6,7 Experimental findings in arterial SMCs
of patients with MMS without NOMID additionally indicated
an important role of IL-1β-induced prostaglandin E2 (PGE2)
overproduction, decreasing vascular tone, increasing vascular
permeability, promoting intimal thickening, and mediating
inhibitory effects on growth and migration of SMCs.2 It is
interesting in this respect that NOMID involves IL-1β
associated BBBI and that our patient with NOMID- and
IL-1β-associated aseptic meningitis and BBBI developed
MMS.5 The causal importance of IL-1β was further sup-
ported by our findings that the systemic inflammation, the
inflammatory CSF markers, the elevated CSF protein in-
dicating BBBI, and the recurrent TIAs responded well to
the treatment escalation from canakinumab to high-dose
anakinra. If the previous experimental hypothesis is correct
that IL-1β-induced PGE2 overproduction is an important
pathway in MMS pathogenesis, NOMID should be a
strong risk factor for MMS. This is suggested by the pre-
sent report and should be further studied in a larger cohort.
On the other hand, IL-1β antagonistic treatment could be
an interesting option for the treatment of MMS in patients
without NOMID, if the IL-1β pathway is generally in-
volved in the pathogenesis of MMS. For example, MMS
can be associated with trisomy 21, hyperthyroidism, sickle
cell disease, and cranial irradiation in all of which IL-1 has
been implicated. Thus, it is speculative at this point in time
and should nevertheless be mentioned that NOMID
could be a Mendelian model disease for MMS. This
places our case in the emerging literature on genetic,
autoinflammation-related vasculopathies that also include
other MMS-associated conditions, such as, for example,
mutations in the SAMHD1 gene.
Table CSF and serum analysis before treatment with IL-1 antagonists at the age of 4 years4 (before IL-1 antagonists),
under canakinumab treatment at admission to our unit at the age of 19 years (canakinumab), 1 week after
treatment escalation from canakinumab to high-dose anakinra (1-week anakinra) and 3 months later under
continued treatment with high-dose anakinra (3 months anakinra)
Before IL-1 antagonists4 Canakinumab 1-week Anakinra 3-months Anakinra
Serum
C-reactive protein (mg/L) 93 23 4.8 2.5
Leukocytes (/nL) 18.2 10.2 5.3 5.4
Serum-amyloid A (mg/mL) 250 317 3 –
IL-1β (pg/mL) – 21 172 76
IL-6 (pg/mL) – 4.0 <2.0 <2.0
IP-10 (pg/mL) – 598 198 –
Calprotectin (μg/mL) – 7.8 2.2 2.6
CSF
IL-1β (normal range: 0.36–0.74 pg/mL) – 14.3 5.8 –
IL-6 (normal range: 2.0–5.8 pg/mL) – 923 4.8 –
IP-10 (normal range: 211–423 pg/mL) – 2,446 623 –
Cell count (/μL) Elevated 368 47 29
Protein (mg/L) Elevated 889.5 411.5 395.1
Pathologic changes are marked in bold. “–” indicates when values were not measured.
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